We believe the risk-benefit profile for our Alzheimer’s drug is acceptable, says Eisai U.S. CEO

Ivan Cheung, Eisai U.S. CEO, joins ‘Closing Bell’ to discuss the results of Eisai’s experimental Alzheimer’s phase three trial, the side effects associated with the Alzheimer’s drug and more.